February 4, 2021 -- PerkinElmer has licensed its Horizon Discovery Chosource Chinese hamster ovary (CHO)-K1GS knockout cell line to Trinomab Biotech in China to produce a human monoclonal antibody drug candidate to fight tetanus toxin.
Trinomab was able to develop its drug candidate utilizing Horizon's Chosource cell line, including a gene-editing glutamine synthetase knockout CHO K1 cell line and well-established GS expression system. A phase I clinical trial in Australia is expected to be completed in August 2021.
More than nine biotherapeutics expressed in the Chosource cell line have progressed to investigational new drug filings, according to PerkinElmer.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
